Digitally‐enabled, person‐centred care (PCC) in allergen immunotherapy: An ARIA‐EAACI Position Paper
Oliver Pfaar, Bernardo Sousa‐Pinto, Nikolaos G. Papadopoulos, Désirée Larenas‐Linnemann, Michał Ordak, Maria J. Torres, Ralph Mösges, Ludger Klimek, Torsten Zuberbier, Paolo Maria Matricardi, Uwe Berger, Markus Berger, Stephanie Dramburg, Vera Mahler, Sanna Toppila‐Salmi, Karl‐Christian Bergmann, Markus Ollert, Salvatore Tripodi, Marek Jutel, Ioana Agache, Ibon Eguíluz‐Gracia, Giorgio Walter Canonica, Cezmi A. Akdiş, Milena Sokołowska, Mikhail Sofiev, Mohamed H. Shamji, W. Czarlewski, João Fonseca, Anna Bedbrook, Jean Bousquet
Abstract
In rhinitis and asthma, several mHealth apps have been developed but only a few have been validated. However, these apps have a high potential for improving person-centred care (PCC), especially in allergen immunotherapy (AIT). They can provide support in AIT initiation by selecting the appropriate patient and allergen shared decision-making. They can also help in (i) the evaluation of (early) efficacy, (ii) early and late stopping rules and (iii) the evaluation of (carried-over) efficacy after cessation of the treatment course. Future perspectives have been formulated in the first report of a joint task force (TF)-Allergic Rhinitis and Its Impact on Asthma (ARIA) and the European Academy of Allergy and Clinical Immunology (EAACI)-on digital biomarkers. The TF on AIT now aims to (i) outline the potential of the clinical applications of mHealth solutions, (ii) express their current limitations, (iii) make proposals regarding further developments for both clinical practice and scientific purpose and (iv) suggest which of the tools might best comply with the purpose of digitally-enabled PCC in AIT.